In addition, COX-2 is considered a biomarker for risk stratification of atypical hyperplasia of breast cancers and promotes the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer, chemical resistance, and osteolytic bone metastasis of breast cancer cells [38–41]. This evidence concerns the gene PTGS2 and breast carcinoma.